Department of Radiology, University of Michigan, Center for Molecular Imaging, Ann Arbor, Michigan, USA.
Prog Mol Biol Transl Sci. 2010;95:237-98. doi: 10.1016/B978-0-12-385071-3.00009-5.
Today molecular imaging technologies play a central role in clinical oncology. The use of imaging techniques in early cancer detection, treatment response, and new therapy development is steadily growing and has already significantly impacted on clinical management of cancer. In this chapter, we overview three different molecular imaging technologies used for the understanding of disease biomarkers, drug development, or monitoring therapeutic outcome. They are (1) optical imaging (bioluminescence and fluorescence imaging), (2) magnetic resonance imaging (MRI), and (3) nuclear imaging (e.g., single-photon emission computed tomography (SPECT) and positron emission tomography (PET)). We review the use of molecular reporters of biological processes (e.g., apoptosis and protein kinase activity) for high-throughput drug screening and new cancer therapies, diffusion MRI as a biomarker for early treatment response and PET and SPECT radioligands in oncology.
如今，分子成像技术在临床肿瘤学中发挥着核心作用。成像技术在癌症早期检测、治疗反应和新疗法开发中的应用正在稳步增长，已经对癌症的临床管理产生了重大影响。在本章中，我们概述了用于了解疾病生物标志物、药物开发或监测治疗效果的三种不同的分子成像技术。它们是（1）光学成像（生物发光和荧光成像），（2）磁共振成像（MRI），和（3）核成像（例如单光子发射计算机断层扫描（SPECT）和正电子发射断层扫描（PET））。我们回顾了用于高通量药物筛选和新癌症疗法的生物过程分子报告物（例如细胞凋亡和蛋白激酶活性）的应用，以及扩散 MRI 作为早期治疗反应的生物标志物和用于肿瘤学的 PET 和 SPECT 放射性配体。
